Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03987217 · ClinicalTrials.gov registry record · Early Phase 1
Resistance Training +/- Creatine for Metastatic Prostate Cancer Patients
A Early Phase 1 study, sponsored by University of Utah.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 73
- Enrollment target
NCT03987217: Completed Early Phase 1 study, sponsored by University of Utah.
NCT03987217 is a Early Phase 1 study that has completed, run by University of Utah. The registered enrollment target is 73 participants, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (38% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03987217, a Early Phase 1 study, has completed, sponsored by University of Utah.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 73 participants
- Enrollment target
Study Summary
This trial studies how well resistance training with or without creatine monohydrate supplement works in improving body composition and health outcomes in patients with prostate cancer that has spread to other places in the body. Resistance training, with or without creatine monohydrate supplement, may help to improve feelings of tiredness and overall physical function in patients with prostate cancer.
Primary Outcome
Assessed by whole-body dual x-ray absorptiometry (DXA) scan.
Interventions
- OTHER Questionnaire Administration
- BEHAVIORAL Exercise Intervention
- DIETARY_SUPPLEMENT Creatine Monohydrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2019-06-17 |
| Est. Completion | 2025-03-10 |
| Phase | Early Phase 1 |
What the finished NCT03987217 record still lists
NCT03987217 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 73 participants, a relatively small participant target, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (38% higher).
The record links to 0 conditions, and to 3 interventions - of which Questionnaire Administration is the first listed.
NCT03987217 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03987217 about?
NCT03987217 is a clinical study titled "Resistance Training +/- Creatine for Metastatic Prostate Cancer Patients". This trial studies how well resistance training with or without creatine monohydrate supplement works in improving body composition and health outcomes in patients with prostate cancer that has spread to other places in the body. Resistance training, with or without creatine monohydrate supplement, ...
What is the current status of trial NCT03987217?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 73 participants. The study started on 2019-06-17. Estimated completion is 2025-03-10.
What interventions are being tested in trial NCT03987217?
The interventions under investigation include: Questionnaire Administration (OTHER), Exercise Intervention (BEHAVIORAL), Creatine Monohydrate (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03987217?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03987217's enrollment target sits among peer trials
73 316th of 2000 higher than 1,683 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03661307 · 73 participants · Phase 1
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
- NCT05386108 · 73 participants · Phase 1
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
- NCT05961592 · 73 participants · Phase 1
R-2487 in Patients With Rheumatoid Arthritis
- NCT06150664 · 73 participants · Phase 1
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI